Study S001688

Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02507128
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 190
Start: 2015-07
Primary completion: 2016-07
Lead sponsor: Chen Wei Ren, MD
Conditions: Acute ST-segment Elevation Myocardial Infarction
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: FALSE

Registered primary outcomes

a change in the prevalence of no-reflow [immediately after PCI]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025460	Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Timmers L, Journal of the American College of Cardiology	2009	Randomized trial	PMID 19195607 DOI	registry reference BACKGROUND:19195607